Trial Profile

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Limosilactobacillus reuteri (Primary) ; Limosilactobacillus reuteri (Primary)
Indications Acute enterocolitis; Necrotising enterocolitis
Focus Registrational; Therapeutic Use
Acronyms Connection
Sponsors Infant Bacterial Therapeutics

14 Nov 2024 Status changed from active, no longer recruiting to completed, according to an Infant Bacterial Therapeutics media release.
31 Jul 2024 This study has been completed in Hungary, according to European Clinical Trial Database records.
20 Jul 2024 This trial has been completed in Poland (End Date: 07 Jul 2024), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com